Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (the "Company") for the month of June 2020, specifically dated June 3, 2020. The filing reports on corporate governance actions taken during an adjourned special general meeting of shareholders and ADS holders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
At the special general meeting held on June 3, 2020, shareholders approved the following material changes:
- A revision of the compensation policy for the Company's office holders.
- The term of compensation for Mr. Abraham Nahmias in his role as the Company's active Chairman.
Details regarding these approvals were previously described in the Company's Proxy Statement furnished as Exhibit 99.1 to a Form 6-K filed on April 22, 2020.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document serves solely to disclose the shareholder approvals mentioned above.
Key Facts for Investor Verification
- Verify the specific terms of the revised compensation policy for office holders.
- Confirm the details of the compensation term approved for Mr. Abraham Nahmias as active Chairman.
- Review the Proxy Statement filed on April 22, 2020 (Exhibit 99.1) for full context on the approved changes.